Versantis AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Subsidiary
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://versantis.com
Clinical Trials
7
Active:4
Completed:0
Trial Phases
2 Phases
Phase 1:5
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (71.4%)Phase 2
2 (28.6%)A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy
Phase 2
Not yet recruiting
- Conditions
- Hepatic EncephalopathyAcute on Chronic Liver Failure (ACLF)Decompensated Cirrhosis
- Interventions
- Drug: VS-01 on top of SOC (Active Treatment Group)Drug: SOC
- First Posted Date
- 2025-05-23
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Versantis AG
- Target Recruit Count
- 24
- Registration Number
- NCT06987968
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
Phase 2
Recruiting
- Conditions
- AscitesAcute-On-Chronic Liver Failure
- Interventions
- Drug: VS-01 on top of SOCOther: SOC (Control Group)
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Versantis AG
- Target Recruit Count
- 60
- Registration Number
- NCT05900050
- Locations
- 🇫🇷
Hôpital Universitaire Pitié Salpêtrière, Paris, France
🇭🇺Debreceni Egyetem Klinikai Központ, Debrecen, Hungary
🇺🇸Mayo Clinic Hospital, Phoenix, Arizona, United States
News
No news found